Financials
| Q3 Trading Update | Oct. 29, 2024 |
| Interim results | Sep. 04, 2024 |
| Unaudited Q2 2024 Trading Update | Jul. 24, 2024 |
| Audited results for the year ended 31 Dec 2023 | May. 10, 2024 |
| Unaudited Full Year Trading Update | Feb. 21, 2024 |
| Q3 2023 U.S. Commercial Highlights | Dec. 07, 2023 |
| Interim results update and business update | Sep. 28, 2023 |
Proxies
| Results of 2024 Annual General Meeting | Jun. 20, 2024 |
| Results of 2023 Annual General Meeting | Jun. 28, 2023 |
| Results of 2022 Annual General Meeting | Jul. 27, 2022 |
| AGM resolutions | Jul. 27, 2022 |
| Results of 2021 Annual General Meeting | Jun. 17, 2021 |
| Results of 2020 Annual General Meeting | Jun. 18, 2020 |
| Result of AGM | Jun. 13, 2019 |
Ownership Update
| PDMR Transaction Notification | Nov. 27, 2023 |
| Holding(s) in Company | Jul. 24, 2023 |
| Grant of share options to the CEO | Jun. 06, 2023 |
| Holding(s) in Company | Jun. 01, 2023 |
| Holding(s) in Company | Jun. 01, 2023 |
| Holding(s) in Company | Jan. 13, 2023 |
| Holding(s) in Company | Jan. 12, 2023 |
Announcements
| Business Update | Nov. 21, 2024 |
| Results from Phase 3 paediatric study | Sep. 25, 2024 |
| ACCRUFeR® Approved by Health Canada | Aug. 27, 2024 |
| Notice of interim results | Aug. 14, 2024 |
| Directorate Change | Jul. 24, 2024 |
| $5.7m Milestone Monetization Agreement with AOP | Jul. 03, 2024 |
| New Drug Application for Accrufer® in South Korea | May. 28, 2024 |